European Journal of Haematology
Overview
The European Journal of Haematology is a reputable scientific journal that focuses on the study and research of various aspects of haematology. It publishes high-quality articles, reviews, and case reports related to blood disorders, including hematological malignancies, bleeding and clotting disorders, transfusion medicine, and stem cell transplantation. The journal serves as a valuable resource for haematologists, researchers, and healthcare professionals seeking to stay updated on the latest advancements in the field.
Details
Details
Abbr.
Eur J Haematol
Start
1987
End
Continuing
Frequency
Ten no. a year
p-ISSN
0902-4441
e-ISSN
1600-0609
Country
United Kingdom
Language
English
Specialty
Hematology
Metrics
Metrics
h-index / Ranks: 3387
95
SJR / Ranks: 4192
944
CiteScore / Ranks: 4260
5.60
JIF / Ranks: 3327
3.1
Recent Articles
1.
Vittayawacharin P, Lee B, Eleimat G, Cao Y, Reid J, Gamayo A, et al.
Eur J Haematol
. 2025 Mar;
PMID: 40088122
Background: Data on bone marrow (BM) findings in secondary hemophagocytic lymphohistiocytosis (sHLH) and their association with overall survival (OS) are limited. Objectives: This study aimed to develop a prognostic model...
2.
Abuhelwa A, Almansour S, Basch E, Al-Shamsi H, Abuhelwa Z, Bustanji Y, et al.
Eur J Haematol
. 2025 Mar;
PMID: 40084510
Objectives: Patient-reported outcomes (PROs), including physical function, have predictive potential for survival but remain underexplored in multiple myeloma (MM). This study evaluates the predictive and prognostic value of PROs for...
3.
Tadmor T, Melamed G, Alapi H, Rokach L
Eur J Haematol
. 2025 Mar;
PMID: 40071509
Background: One of the limiting toxicities of BTKi is the development of atrial fibrillation (AF), with an incidence of 3%-16%. Aim: This study aimed to identify patients with chronic lymphocytic...
4.
Chung C, Doan D
Eur J Haematol
. 2025 Mar;
PMID: 40066747
Although small molecule inhibitors that target the aberrant signaling pathways and molecular defects of chronic lymphocytic leukemia (CLL) result in improved survival benefits vs. traditional chemoimmunotherapy or chemotherapy, treatment resistance...
5.
Nagafuji K, Ito Y, Miyamoto T, Eto T, Kamimura T, Kato K, et al.
Eur J Haematol
. 2025 Mar;
PMID: 40052397
Aim: To assess the efficacy of continuous dasatinib in improving outcomes for adult patients with BCR::ABL1 ALL. Methods: The prospective, multicenter ALL/MRD2014 trial introduced a modified protocol compared to the...
6.
7.
Bruzzese A, Martino E, Labanca C, Carida G, Mendicino F, Lucia E, et al.
Eur J Haematol
. 2025 Mar;
PMID: 40045912
The treatment landscape for relapsed or refractory acute lymphoblastic leukemia (RR ALL) has evolved significantly with the introduction of monoclonal antibodies such as blinatumomab and inotuzumab ozogamicin. These agents have...
8.
Burceaga F, Cardenas A, Ortega J, Galvan E
Eur J Haematol
. 2025 Mar;
PMID: 40035213
Aplastic Anemia (AA) is a rare blood disorder where the bone marrow fails, leading to pancytopenia. Most of the time it is idiopathic; however, it can also be caused by...
9.
Ghimire B, Zimmer M, Donthireddy V
Eur J Haematol
. 2025 Mar;
PMID: 40035191
Patients with acute myeloid leukemia (AML) harboring mutations in TP53 (TP53-MT) have poor responses to current therapies and unfavorable prognoses. Despite the recognition of variant TP53 as an adverse feature...
10.
Hughes M, Balev M, Radhakrishnan J, Bhutani D, Mapara M, Lentzsch S, et al.
Eur J Haematol
. 2025 Feb;
PMID: 39989117
Myeloma cast nephropathy (MCN) is a driver of renal failure in newly diagnosed multiple myeloma (NDMM) and has been historically associated with increased early mortality. Since patients with moderate to...